ICObench
Tron Logo
Trade on HitBTC
Like this video

Dermavir

Dendritic Cell-Targeting Therapeutic Vaccine

We are a privately held clinical-stage biotechnology company focusing on the development and commercialization of a revolutionary new immune therapy platform for the treatment of chronic viral infections, cancer and allergy. Our technology is designed to boost specific immune response in order to modify or control presently incurable diseases. Our proprietary Vaccine Platform includes a given disease’s antigen specific plasmid DNA (pDNA), a nanomedicine formulation which encapsulates the pDNA to make it closely resemble a virus (we call this combination a nanoparticle), a topical (through the skin) administration device we call DermaPrep which delivers the vaccine via dendritic cell to lymph nodes of the immune system, and a software product which allows us to design antigen specific pDNA and closely match it to a patient’s genetic and HLA profile. The combination of these technologies supports the rapid and cost-effective development of original biologic vaccine products.

2.9
4 3 expert ratings
Benchy 2.6
KYC
Experts
3.0
5.0
2.1
Review: coming soon PRO

Unknown
Token
DER
Type
PreICO Price
1 DER = 0.70 USD
Price
1 DER = 1 USD
Bonus
Available
Platform
Accepting
ETH
Minimum investment
0.1 ETH
Hard cap
10,000,000
Country
USA
Whitelist/KYC
KYC
Visit ICO website
Report

About Dermavir

Genetic Immunity is a US clinical-stage biotechnology company focusing on the discovery, development and commercialization of a new class of therapeutic vaccines ("Immune Therapies") for the treatment of chronic viral infections (HIV, HPV), cancer and allergies. Our Immune Therapies are designed to intensify and boost specific immune response to modify or control these presently incurable diseases. We believe our products will allow people to live better, healthier and longer lives.

Our proprietary immunotherapy platform is composed of an pDNA (plasmid DNA) expressing multiple disease specific antigens, a nanomedicine formulation encapsulating the pDNA and a topical administration device which targets the formulation transdermally to dendritic (Langerhans) cells of the skin. Our platform technologies support the rapid and cost-effective development of novel biologic products for several indications and provides tools for the selection of an optimal, patient specific treatment regimen.

Our Lead Product Candidate, a therapeutic vaccine for the treatment of HIV is effective in boosting immune response to kill HIV-infected cells. Our preclinical, Phase I, Phase I/II and Phase II trials have demonstrated HIV-specific T-cells immune response and boosting, and the killing of HIV-infected cells. DermaVir has an excellent safety profile. Our goal is to provide DermaVir as a co-treatment option to antiretroviral therapy (ART), and, upon the completion of an additional clinical trial, to demonstrate efficacy in ART resistant patients, thereby opening a safe, effective new treatment paradigm.

In addition to HIV we also work on an extensive pipeline including therapeutic treatments for cancer, the human papillomavirus, MAGE, allergies and more.

Please see our pipeline of virus-associated cancers and warts in discovery phase section of the website.

Add to bookmarks
ICO KYC Report
Not conducted yet
KYC procedure verifies selected/specific team members only. It does not guarantee ICO success nor is a call for investment.
Missing or incorrect data? Let us know.

ICOs that might interest you

4.4

HiveNet

HiveNet is a distributed cloud computing network, which enables computer owners to rent...

29 days 22 hours left
4.8

Max Crowdfund

Max Crowdfund is an International Real Estate Crowdfunding Platform and Property Manage...

52 days 12 hours left
4.5

Freelanex

Freelanex is a decentralized platform which provides an environmental system on Blockch...

6 hours left
4.6

Mindsync

Mindsync is a platform to solve customer's tasks with AI technologies competitions as w...

6 days 22 hours left

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Learn more Got it